COVID-19 vaccine: BioNTech and Pfizer report 90% effectiveness in trials

10 November 2020
234 Views

Germany’s BioNTech and its US pharma partner Pfizer announced on Monday that their vaccine candidate is more than 90% effective in preventing COVID-19 in a trial of over 43,000 participants.

“Today is a great day for science and humanity,“ said Dr Albert Bourla, chairman and CEO of Pfizer in a statement. “The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19.”

Based on current projections from the company, it expects to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

Bourla said that they are “reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen”.

Source: yahoo

You may be interested

Immediate US sanctions against Turkey for S-400 system
WORLD
shares32 views
WORLD
shares32 views

Immediate US sanctions against Turkey for S-400 system

makis - Dec 04, 2020

The 2021 National Defense Authorization Act (NDAA) provides for the imposition of sanctions against Turkey for the acquisition of the…

Covid-19 Greece – 1,882 new cases on Thursday
GREECE
shares44 views
GREECE
shares44 views

Covid-19 Greece – 1,882 new cases on Thursday

makis - Dec 03, 2020

The Greek authorities announced 1,882 new cases of coronavirus on Thursday, 8 of which were detected following checks at the…

Greek Shipping Minister admitted to ICU
GREECE
shares49 views
GREECE
shares49 views

Greek Shipping Minister admitted to ICU

Panos - Dec 03, 2020

The Minister of Shipping and Island Policy, Giannis Plakiotakis, was admitted for precautionary reasons to the Intensive Care Unit of…

Leave a Comment

Your email address will not be published.